Volume 16, Number 1—January 2010
Letter
Skin Lesion Caused by ST398 and ST1 MRSA, Spain1
Table
Characteristics of the 9 MRSA strains recovered in Spain from a patient’s lesion and from nasal samples obtained from patient’s family members*
Strain | Origin of sample | SCCmec type | MLST | spa type | agr | Antimicrobial resistance phenotype | Resistance genes detected | Amino acid change in: |
|
---|---|---|---|---|---|---|---|---|---|
GrlA | GyrA | ||||||||
C1570 | Patient/ skin lesion | V | ST398 | t011 | I | OXA, FOX, TET, ERY, CLI, TEL | mecA, tetK, ermA, ermC, msrA | NP | NP |
C1569 | Patient/ skin lesion | II | ST1 | t127 | III | OXA, FOX, TET, ERY, CLI, TEL, GEN, TOB, KAN, CIP, LEV, SXT | mecA, tetL, tetK, ermA, ermB, ermC, msrA, aph(2’)-acc(6’), ant(4´)-Ia, aph (3’), dfrK | S80F | S84L |
C1571 | Patient/ nasal swab | V | ST398 | t108 | I | OXA, FOX, TET, ERY, CLI, TEL, CIP†, LEV† | mecA, tetK, tetL, tetM, ermA, ermC, msrA | Wild | Wild |
C1577 | Mother/ nasal swab | V | ST398 | t108 | I | OXA, FOX, TET, ERY, CLI, TEL, CIP†, LEV† | mecA, tetK, tetM, ermA, ermC, msrA | Wild | Wild |
C1578 | Mother/ nasal swab | II | ST1 | t127 | III | OXA, FOX, TET, ERY, CLI, TEL, GEN, TOB, KAN, CIP, LEV, SXT | mecA, tetL, tetK, ermA, ermB, ermC, msrA, aph(2’)-acc(6’), ant(4´)-Ia, aph (3’), dfrK | S80F | S84L |
C1574 | Brother/ nasal swab | V | ST398 | t011 | I | OXA, FOX, TET, ERY, CLI, TEL | mecA, tetK, ermA, ermC, msrA | NP | NP |
C1576 | Brother/ nasal swab | V | ST398 | t011 | I | OXA, FOX, TET, ERY, CLI, TEL, GEN, TOB, KAN, SXT | mecA, tetL, tetK, ermA, ermB, ermC, msrA, aph(2’)-acc(6’), ant(4´)-Ia, aph (3’), dfrK | NP | NP |
C1572 | Father/ nasal swab | V | ST398 | t108 | I | OXA, FOX, TET, ERY, CLI, TEL, CIP†, LEV† | mecA, tetK, tetL, tetM, ermA, ermC, msrA | Wild | Wild |
*MRSA, methicillin resistant Staphylococcus aureus; SCC, staphylococcal cassette chromosome; MLST, multilocus sequence typing; ST, sequence type; OXA, oxacillin; FOX, cefoxitin; TET, tetracycline; ERY, erythromycin; CLI, clindamycin; TEL, telithromycin; NP, not performed; GEN, gentamicin; TOB, tobramycin; KAN, kanamycin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, sulfamethoxazole-trimethoprim.
†Iintermediate category for the indicated antimicrobial drug.
1This study was presented as a poster at the 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, 2009.
Page created: March 31, 2011
Page updated: March 31, 2011
Page reviewed: March 31, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.